that CycLuc1 exhibits properties superior to those of d-luciferin in vivo, requiring less substrate for imaging and providing more intense and persistent light output. Moreover, this substrate enabled imaging of luciferase-expressing cells in the brains of live mice that could not be observed with d-luciferin. Thus, using CycLuc1 in place of d-luciferin expands the scope of bioluminescence imaging with existing luciferase-expressing reporters.
Efforts to improve the sensitivity of in vivo BLI have largely focused on improving the expression levels of firefly luciferase 4, 5 or identifying mutations that redshift the emitted light to wavelengths that more readily penetrate tissues 6 . Much less attention has been focused on modulating the properties of luciferin, despite the importance of its cell permeability and pharmacokinetic properties in vivo. In standard BLI, relatively high concentrations of d-luciferin are required (150 mg/kg is the typical dose for routine intraperitoneal (i.p.) injections, which equates to 0.1 ml of 100 mM d-luciferin for an average 20-g mouse). d-Luciferin is also only modestly cell permeable 7, 8 , and experiments with radiolabeled substrate have shown that its tissue distribution is not homogeneous and that its uptake into some organs, such as the brain, is low 9 . Thus, d-luciferin may not be the optimal substrate for imaging in the mouse.
Synthetic luciferins have not yet shown improvement over standard imaging with d-luciferin in live mice, a difficulty that likely reflects issues including poor cell permeability 7, 8, 10, 11 , biodistribution 10, 11 , less efficient light emission, and similar or weaker red light (tissue-penetrating) emission compared to a synthetic luciferin improves bioluminescence imaging in live mice firefly luciferase is the most widely used optical reporter for noninvasive bioluminescence imaging (bLi) in rodents. bLi relies on the ability of the injected luciferase substrate d-luciferin to access luciferase-expressing cells and tissues within the animal. here we show that injection of mice with a synthetic luciferin, cycLuc1, improves bLi with existing luciferase reporters and enables imaging in the brain that could not be achieved with d-luciferin.
BLI with firefly luciferase is a powerful and popular method to noninvasively visualize molecular and cellular features in live mice [1] [2] [3] . Firefly luciferase produces light chemically from its small-molecule substrate, d-luciferin. Introduction of these components into cells or whole animals produces light that can be captured by sensitive detectors. The inherent simplicity of this imaging method has led to its ubiquitous adoption for in vivo monitoring of numerous disease states and cellular functions [1] [2] [3] . Improvements to the sensitivity and dynamic range of BLI are therefore of immediate and general utility for a wide variety of applications.
Here Recently, a variety of new substrates for firefly luciferase have been reported 13, 14 , including substrates with alkylated 6′-amino groups 15, 16 . All of these luciferin analogs yield substantially lower light emission than d-luciferin with the wild-type firefly luciferase in vitro 10, 15, 16 . However, some substrates, such as the cyclic alkylaminoluciferin CycLuc1, exhibit improved light output relative to d-luciferin in live cells when compared at low substrate concentrations (e.g., <10 µM) 7 . Although d-luciferin yields superior photon flux from live cells when supplied at higher concentrations, we hypothesized that CycLuc1 could perform relatively well in vivo if the actual intracellular concentration of luciferin achieved in the mouse were limiting. To evaluate CycLuc1 in vivo, we first tested its ability to image well-established mouse xenograft tumor models. We implanted 4T1 breast cancer cells expressing luc2 luciferase (4T1-luc2) into the mammary fat pads of BALB/c mice and imaged the mice 8 d after engraftment. Intraperitoneal injection of CycLuc1 yielded a >10-fold higher bioluminescent signal than could be obtained from d-luciferin injection at equivalent doses ( Fig. 1 and Supplementary Fig. 1) . Surprisingly, a 20-to 200-fold lower dose of CycLuc1 yielded the same peak photon flux as the standard imaging conditions of 150 mg/kg d-luciferin ( Fig. 1c and Supplementary Fig. 2 ). CycLuc1 doses up to 2,000fold lower than the standard doses of d-luciferin could be imaged, whereas equivalent concentrations of d-luciferin provided either weak or no signal ( Fig. 1) . One hour after injection, the difference in emission from CycLuc1 was even more pronounced, primarily due to a tenfold drop in d-luciferin light emission over this period (Supplementary Fig. 1 ). The improved performance of CycLuc1 also translated across different cell types, mouse strains and implantation sites. Photon flux from luciferaseexpressing DB7 breast cancer cells (DB7-luc) implanted in the hind flanks of FVB mice was up to 40-fold higher with CycLuc1 as compared to d-luciferin administration at an equivalent dose ( Supplementary Fig. 3 ). CycLuc1 also enabled detection of luciferase-expressing CMT-64 lung cancer cells implanted into the hind flank of C57BL/6 mice, one of the most widely used mouse strains, providing increased signal intensity at all doses examined ( Supplementary Fig. 4) .
Next, to compare the distribution and trafficking of CycLuc1 and d-luciferin in vivo, we used a mouse that expresses luciferase in most tissues (L2G85-FVB) 17 . Consistent with results from previous studies, i.p. injection of d-luciferin revealed access to tissues throughout the mouse, albeit with the highest photon flux confined to the abdominal cavity near the site of injection ( Fig. 2) 8 . In contrast, i.p. injection of CycLuc1 revealed a bioluminescent signal that was tenfold higher in intensity and escaped from the abdominal cavity to give a broad distribution that was maintained for up to 2 h (Fig. 2) . Comparison of intravenous (i.v.) injections was even more striking: CycLuc1 signal peaked at 4-5 min after injection and then yielded a steady signal that was up to 100-fold greater than that of d-luciferin and persisted for more than 60 min (Supplementary Figs. 5 and 6) . By contrast, with d-luciferin the signal peaked immediately after injection and dissipated over 20 min (Supplementary Figs. 5 and 6) .
In light of these results, we asked whether CycLuc1 could improve bioluminescent signals in the brain. The blood-brain npg barrier limits the access of many small molecules to this tissue, and thus imaging in the brain is particularly challenging. To evaluate the ability of CycLuc1 to access brain tissue, we imaged mice that had been treated with adeno-associated virus 9 (AAV9) 18 to express codon-optimized luc2 luciferase in the brain striatum. We found that upon i.p. injection CycLuc1 provided an 8.1 ± 1.5-fold higher signal than d-luciferin, despite a 20-fold lower dose of CycLuc1 ( Fig. 3 and Supplementary Fig. 7) . Thus, CycLuc1 can readily cross the blood-brain barrier and access deep brain tissues. Next, we crossed Dat (also known as Slc6a3) Cre driver mice with Rosa26 floxed-stop luciferase reporter mice 19 . In the offspring from this cross, Dat-Cre drives luc reporter expression at low levels from the endogenous Rosa26 promoter in dopaminergic neurons, primarily in the substantia nigra, one of the deepest brain tissues 20 . Injection of these mice with d-luciferin failed to yield any measurable brain signal in vivo ( Fig. 3 and Supplementary  Fig. 8) .
In sharp contrast, we found that not only did CycLuc1 enable imaging in these same animals, but homozygous mice with two copies of the Rosa26-luc allele could be readily distinguished from heterozygous mice by a 1.9 ± 0.2-fold higher photon flux ( Fig. 3 and Supplementary Fig. 8) .
The improved sensitivity of BLI with CycLuc1 has immediate ramifications for biological studies in mice. Simply replacing injected d-luciferin with injected CycLuc1 improves the sensitivity of bioluminescence detection with existing luciferase reporters. CycLuc1 allows imaging at low doses where d-luciferin provides weak or no signal. Furthermore, CycLuc1 enables detection of low-level luciferase expression in deep brain tissues that cannot be achieved with d-luciferin, and thus it opens up new applications for noninvasive imaging in the brain. One potential contributor to the improved in vivo performance of CycLuc1 is a redshift in the emitted photons to more tissue-penetrating wavelengths (Supplementary Fig. 9 ) 7, 15 . However, the percentage of Cy5.5-filtered flux from the brains of live AAV-treated mice is actually slightly higher for d-luciferin than for CycLuc1 (9.4% versus 8.1%; Supplementary Fig. 10) , perhaps reflecting the redshift in luciferase emission previously reported at 37 °C in vivo 12 . Moreover, a change in emission wavelength alone cannot explain the differences we observed in tissue distribution, signal persistence and the ability to image at very low substrate concentrations. In cell culture, the luciferase-expressing 4T1, DB7 and CMT-64 tumor cells yield higher bioluminescent signals with d-luciferin except at low substrate concentrations, where CycLuc1 is favored (Supplementary Fig. 9 ). In vivo these same cells yield greater photon flux with CycLuc1, even in tumors that are located near the surface and/or proximal to the site of substrate injection. This suggests that the delivery of d-luciferin to luciferase-expressing cells in vivo is limiting, and that the cell permeability, lower K m (ref. 7) and bioavailability of CycLuc1 play important roles in its superior in vivo performance.
On the basis of our results, CycLuc1 can be recommended for immediate use in BLI, while future adaptation of related synthetic luciferins and mutant luciferases 7 is expected to allow even greater improvements in the sensitivity, selectivity and scope of in vivo bioluminescent reporters.
methods
Methods and any associated references are available in the online version of the paper. onLine methods General methods. d-Luciferin and CycLuc1 were synthesized as previously described 13, 15 . Luciferase-expressing 4T1 cells, CMT-64 cells and DB7 cells were provided by the Contag laboratory (Stanford University).
Mice. Pathogen-free BALB/c, FVB/N, C57BL/6 and luciferaseexpressing transgenic mice (FVB-Tg(CAG-luc,-GFP)L2G85Chco/ FathJ) 17 were obtained from either Charles River Laboratories or the Jackson Laboratory and housed in the University of California, Irvine (UC Irvine)'s AAALAC-accredited animal care facility. All mice used were littermates or age-matched (6-12 weeks of age) females, were provided access to food and water ad libitum, and were housed in the animal facilities at UC Irvine. All procedures with these mice were approved by the Animal Care and Use Committee at UC Irvine (protocol #2011-2987 to J.A.P.). FVB/NJ, B6.SJL-Slc6a3 tm1.1(cre)Bkmn /J ("Dat-Cre") 21 and FVB.129S6(B6)-Gt (ROSA)26Sor tm1(Luc)Kael /J ("Rosa26-luc") 19 mice were purchased from the Jackson Laboratory and were maintained and used according to the guidelines of the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School (docket #A978-12 to N.A.). Dat-Cre mice were mated with floxed-stop Rosa26-luc mice to generate white Dat-Cre +/− Rosa26-luc +/− and Dat-Cre +/− Rosa26-luc +/+ mice. Offspring were genotyped by PCR.
Tumor cell inoculations. Mice were inoculated subcutaneously with 1 × 10 6 luciferase-expressing CMT-64 or DB7 cells in serumfree RPMI medium. Tumors were allowed to establish for 1-2 weeks before imaging. To establish 4T1 tumors, aliquots of the cells were mixed 1:1 by volume with Matrigel (usually 5 × 10 5 cells in 50 µl serum-free DMEM medium plus 50 µl Matrigel per injection) and transplanted into the orthotopic second or fourth mammary fat pads (left or right side) of mice. At 8 d after engraftment, the mice were injected i.p. with 100 µl of either d-luciferin or CycLuc1 (50 µM to 5 mM) and imaged 10 min after injection.
Bioluminescence imaging. To image tumor cells in vivo, mice were injected i.p. with 100 µl of luciferin stocks (in PBS). The animals were anesthetized with isoflurane (2% in 1 l/min oxygen), and bioluminescence images were acquired using the IVIS Lumina system (a Xenogen product from Caliper Life Sciences, now PerkinElmer). Images were acquired every 2 min for 30 min (10-s exposure per image). The mice were also imaged 1 h and 2 h after injection (10-s exposure per image). Images were analyzed using Living Image software. Regions of interest (ROIs) were drawn around each cell mass, and the total numbers of photons within each ROI were recorded. ROI size was held constant across all images. Before being imaged with CycLuc1, the mice were stratified using standard BLI conditions (100 µl i.p. injection of 100 mM d-luciferin in PBS).
To analyze the biodistribution of d-luciferin and CycLuc1 in vivo, the compounds were injected (100 µl of 5 mM solutions in PBS) i.p. or i.v. into luciferase-expressing FVB transgenic mice. The mice were imaged over time as described above, and quantitative analyses of the light emission were performed using Living Image software as above.
Construction of AAV-CMV-luc2. Codon-optimized luc2 luciferase from pGL4 (Promega) was cloned into the EcoRI-SalI sites of a pAAV-CMV vector (gift of G. Gao, University of Massachusetts Medical School). The plasmid was packaged into AAV serotype 9 by the University of Massachusetts Medical School Viral Vector Core.
AAV9-CMV-luc2 vector striatal injections. FVB/NJ mice (5 females, 6 weeks old, Jackson Laboratory) were anesthetized with 250 mg/kg tribromoethanol before surgery, placed on a stereotactic frame and injected with 0.25 µL 1e13 GC AAV9-CMV-Luc2 by micropump syringe (NanoFil, World Precision Instruments) at the lateral edge of the striatum/cortex border (anterior 1 mm, lateral 3 mm and ventral 2 mm from bregma). Imaging was performed at least 2 weeks after AAV injection.
Brain imaging. Bioluminescence imaging of luciferaseexpressing mice was performed as described above in the University of Massachusetts Medical School Small Animal Imaging Core using an IVIS 100 imaging system and analyzed with Living Image software and GraphPad Prism 6. 
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